Botulinum toxin in childhood strabismus

Area of Science:

• Ophthalmology
• Pediatric Medicine
• Neurology

Background:

• Childhood strabismus management remains debated.
• Botulinum toxin A (BTXA) is increasingly considered for pediatric strabismus.
• Evaluating BTXA's efficacy and indications in children is crucial.

Purpose of the Study:

• To investigate the indications and outcomes of BTXA therapy in pediatric strabismus patients.
• To assess BTXA's effectiveness in improving binocular function.
• To evaluate BTXA's role in diagnostic and therapeutic contexts for complex strabismus.

Main Methods:

• Retrospective study of 163 children (up to 16 years) treated with BTXA for strabismus between 1985-1995.
• Analysis of patient age, anesthesia, injection details, indications, outcomes, complications, and follow-up.
• Categorization of indications into improving binocular function, post-operative diplopia testing/cosmetic alignment, and investigating paralytic/restrictive strabismus.

Main Results:

• Improved binocular function was achieved in 54% of patients in the first indication group (n=54).
• BTXA provided informative post-operative diplopia tests in 88% of the second group (n=82), with 44% requiring multiple injections for cosmetic alignment.
• The third group (n=27) with paralytic/restrictive strabismus showed varied outcomes, highlighting BTXA's diagnostic utility.

Conclusions:

• Botulinum toxin A is a valuable therapeutic tool for specific pediatric strabismus cases.
• BTXA is indicated when there's risk to binocularity or potential for worsened diplopia post-surgery.
• The toxin demonstrates diagnostic value in evaluating strabismus of unusual etiology in children.